Skip to main content
DBD
NYSE Technology

10% Owner Sells $33M in Diebold Nixdorf Stock Near 52-Week High

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Software Stocks · Technology
Sentiment info
Negative
Importance info
7
Price
$84.78
Mkt Cap
$2.982B
52W Low
$36.425
52W High
$85.99
52W Position info
133% above low
Off High info
1.4% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

DBD has more than doubled off its 52-week low of $36.425.

Summary

Millstreet Capital Management and its managing members, a 10% owner of Diebold Nixdorf, sold over $32.9 million worth of common stock, reducing their stake while the stock trades near its 52-week high.


Key Events · Ownership and Investor Activity · DBD

  • Significant Insider Sale

    Millstreet Capital Management LLC, a 10% owner, along with managing members Brian D Connolly and Craig Kelleher, disposed of 399,929 shares of common stock.

  • Substantial Value

    The open market sale totaled $32,960,468 at an average price of $82.42 per share on April 8, 2026.

  • Position Reduction

    This transaction reduces their collective holdings to 4,816,743 shares, representing a 7.66% reduction in their prior stake.

  • Timing Near 52-Week High

    The sale occurred while Diebold Nixdorf's stock is trading near its 52-week high of $85.99, potentially indicating profit-taking.


Analysis · DBD · Technology

This significant open market sale by a 10% institutional owner, Millstreet Capital Management, and its managing members, represents a substantial disposition of shares. While not an operational insider, the sale of over $32.9 million worth of stock, equivalent to more than 1% of the company's market capitalization, indicates a notable reduction in their position. The transaction occurred with the stock trading near its 52-week high, suggesting the investors may be locking in gains. This follows Diebold Nixdorf's strong financial rebound reported in February, which included a new share repurchase program, but this sale by a major investor could introduce some selling pressure.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 36.3% of the 2976 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DBD was trading at $84.78 on NYSE in the Technology sector, with a market capitalization of approximately $3B. The 52-week trading range was $36.43 to $85.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DBD - Latest Insights

DBD
Oct 28, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.00
Real-time Price: $58.27 info
Change: +$1.27 (+2%) info
Market Cap: $1.957B info
DBD
Oct 28, 2026, 7:17 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $67.49
Real-time Price: $58.27 info
Change: -$9.22 (-14%) info
Market Cap: $1.957B info
DBD
Oct 28, 2026, 7:06 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $67.49
Real-time Price: $58.27 info
Change: -$9.22 (-14%) info
Market Cap: $1.957B info
DBD
Oct 05, 2026, 2:47 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $65.58
Real-time Price: $58.27 info
Change: -$7.31 (-11%) info
Market Cap: $1.957B info
DBD
Jul 31, 2026, 4:27 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $73.93
Real-time Price: $58.27 info
Change: -$15.66 (-21%) info
Market Cap: $1.957B info